Portal de Periódicos da CAPES

Adenovirus-Based Phospholamban Antisense Expression as a Novel Approach to Improve Cardiac Contractile Dysfunction

2000; Lippincott Williams & Wilkins; Volume: 101; Issue: 18 Linguagem: Inglês

10.1161/01.cir.101.18.2193

1524-4539

Karin Eizema, Henry Fechner, Karel Bezstarosti, Sonja Schneider-Rasp, Arnoud van der Laarse, Haili Wang, Heinz‐Peter Schultheiß, Wolfgang Poller, Jos M. J. Lamers,

Cardiac electrophysiology and arrhythmias

Background —A decrease in sarcoplasmic reticulum Ca 2+ pump (SERCA2) activity is believed to play a role in the impairment of diastolic function of the failing heart. Because the expression ratio of phospholamban (PL) to SERCA2 may be a target to improve contractile dysfunction, a PL antisense RNA strategy was developed under the control of either a constitutive cytomegalovirus (CMV) or an inducible atrial natriuretic factor (ANF) promoter. The latter is upregulated in hypertrophied and failing heart, allowing “induction-by-disease” gene therapy. Methods and Results —Part of the PL cDNA was cloned in antisense and sense directions into adenovectors under the control of either a CMV (Ad5CMVPLas and Ad5CMVPLs, respectively) or ANF (Ad5ANFPLas and Ad5ANFPLs, respectively) promoter. Infection of cultured rat neonatal cardiomyocytes with Ad5CMVPLas reduced PL mRNA to 30±7% of baseline and PL protein to 24±3% within 48 and 72 hours, respectively. The effects were vector dose dependent. Ad5CMVPLas increased the Ca 2+ sensitivity of SERCA2 and reduced the time to 50% recovery of the Ca 2+ transient. A decrease of PL protein was also achieved by infection with Ad5ANFPLas, and the presence of the hypertrophic stimulus, endothelin-1, led to enhanced downregulation of PL. The adenovectors expressing PL sense RNA had no effect on any of the tested parameters. Conclusions —Vector-mediated PL antisense RNA expression may become a feasible approach to modulate myocyte Ca 2+ homeostasis in the failing heart. The inducible ANF promoter for the first time offers the perspective for induction-by-disease gene therapy, ie, selective expression of therapeutic genes in hypertrophied and failing cardiomyocytes.